IceCure Medical (NASDAQ:ICCM - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $2.50 price objective on the stock. HC Wainwright's price objective suggests a potential upside of 138.10% from the stock's current price.
IceCure Medical Price Performance
NASDAQ:ICCM traded up $0.02 during trading hours on Thursday, reaching $1.05. 166,926 shares of the company's stock were exchanged, compared to its average volume of 475,826. The company has a market capitalization of $58.28 million, a P/E ratio of -3.62 and a beta of 0.41. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.66. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. The business's 50-day simple moving average is $1.11 and its two-hundred day simple moving average is $1.14.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last posted its quarterly earnings data on Wednesday, May 28th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. The firm had revenue of $0.73 million during the quarter, compared to analyst estimates of $0.75 million. During the same quarter last year, the business posted ($0.08) EPS. Sell-side analysts expect that IceCure Medical will post -0.28 EPS for the current fiscal year.
Hedge Funds Weigh In On IceCure Medical
An institutional investor recently raised its position in IceCure Medical stock. XTX Topco Ltd increased its position in IceCure Medical Ltd (NASDAQ:ICCM - Free Report) by 123.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 58,866 shares of the company's stock after purchasing an additional 32,555 shares during the period. XTX Topco Ltd owned about 0.11% of IceCure Medical worth $65,000 at the end of the most recent reporting period. 0.62% of the stock is owned by institutional investors.
IceCure Medical Company Profile
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Recommended Stories
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
